Tafamidis Should Be Accessible for All Patients With ATTR-CM Tafamidis Should Be Accessible for All Patients With ATTR-CM

Tafamidis, a daily, orally available medication, has proven highly effective in the treatment of transthyretin amyloid cardiomyopathy, but its high cost puts it out of reach of most patients.JACC: Heart Failure
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news